Therefore, RIG-I agonists have been combined with checkpoint inhibitors, with the addition of the agonist overcoming tumour resistance to anti-PD-1 and anti-CTLA4 by enhancing tumour cell death and cross-priming by cDC1s to potentiate systemic cytotoxic T lymphocyte (CTL) antitumour responses [49,149]. This evidence concerns the gene RIGI and neoplasm.